Quality Of Life While Receiving Faslodex

Completed

• Conditions: Breast Cancer

• Registration Number: NCT00643513
• Lead Sponsor: AstraZeneca

Brief Summary

To study QoL related response, symptom spectrum and severity in disseminated breast cancer patients receiving Faslodex hormonal therapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-06
• Study First Submitted: 2008-03-20
• Study First Submitted QC: 2008-03-20
• Study First Posted: 2008-03-26
• Study Completion: 2009-01
• Status Verified: 2009-04
• Last Update Submitted: 2009-04-21
• Last Update Posted: 2009-04-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Histologic and/or cytological proven breast cancer.
• Patients with metastases of breast cancer ± postmenopausal primary tumor ≥12 months.
• Positive oestrogen receptors (ER+), positive progesterone receptors (PgR+) or unknown hormonal receptors (if duration between surgery and metastasis occurring is not less 2 years) which are indirect confirmation of hormone sensitive tumor.
• ECOG performance status of ≤ 2
• Patient willingness to take part in the programm
• Life expectancy of more than 6 months.
• Patient ability to complete a questionnaire.

Read More

Exclusion Criteria

• Contraindications for Faslodex therapy
• Other anticancer therapy (chemotherapy, hormonal therapy with other drugs, radiotherapy), except for radiotherapy of sites which are not only measurable or evaluable manifestation of disease.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To study QoL related response, symptom spectrum and severity in disseminated breast cancer patients receiving Faslodex hormonal therapy.

Trial Locations

Locations (1)

Research Site; 🇷🇺 Yakutsk, Russian Federation